Abstract:Hepatitis C virus (HCV) entry into host cells is a multistep process requiring various host factors, including the tight junction protein occludin (OCLN), which has been shown to be essential for HCV infection in in vitro cell culture systems. However, it remains unclear whether OCLN is an effective and safe target for HCV therapy, owing to the lack of binders that can recognize the intact extracellular loop domains of OCLN and prevent HCV infection. In this study, we successfully generated four rat anti-OCLN monoclonal antibodies (MAbs) by the genetic immunization method and unique cell differential screening. These four MAbs bound to human OCLN with a very high affinity (antibody dissociation constant of <1 nM). One MAb recognized the second loop of human and mouse OCLN, whereas the three other MAbs recognized the first loop of human OCLN. All MAbs inhibited HCV infection in Huh7.5.1-8 cells in a dose-dependent manner without apparent cytotoxicity. Additionally, the anti-OCLN MAbs prevented both cell-free HCV infection and cell-to-cell HCV transmission. Kinetic studies with anti-OCLN and anti-claudin-1 (CLDN1) MAbs demonstrated that OCLN interacts with HCV after CLDN1 in the internalization step. Two selected MAbs completely inhibited HCV infection in human liver chimeric mice without apparent adverse effects. Therefore, OCLN would be an appropriate host target for anti-HCV entry inhibitors, and anti-OCLN MAbs may be promising candidates for novel anti-HCV agents, particularly in combination with direct-acting HCV antiviral agents.IMPORTANCE HCV entry into host cells is thought to be a very complex process involving various host entry factors, such as the tight junction proteins claudin-1 and OCLN. In this study, we developed novel functional MAbs that recognize intact extracellular domains of OCLN, which is essential for HCV entry into host cells. The established MAbs against OCLN, which had very high affinity and selectivity for intact OCLN, strongly inhibited HCV infection both in vitro and in vivo Using these anti-OCLN MAbs, we found that OCLN is necessary for the later stages of HCV entry. These anti-OCLN MAbs are likely to be very useful for understanding the OCLN-mediated HCV entry mechanism and might be promising candidates for novel HCV entry inhibitors.

Occludin‐binding single‐chain variable fragment and antigen‐binding fragment antibodies prevent hepatitis C virus infection

Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model

Human-rat chimeric anti-occludin monoclonal antibodies inhibit hepatitis C virus infection

Occludin-Knockout Human Hepatic Huh7.5.1-8-Derived Cells Are Completely Resistant to Hepatitis C Virus Infection

Development of an effective single-chain variable fragment recognizing a novel epitope in the hepatitis C virus E2 protein that restricts virus entry into hepatocytes

Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants

Single-domain intrabodies against hepatitis C virus core inhibit viral propagation and core-induced NFκB activation

Role of the cytosolic domain of occludin in trafficking and hepatitis C virus infection

An E. Coli-Produced Single-Chain Variable Fragment (scfv) Targeting Hepatitis B Virus Surface Protein Potently Inhibited Virion Secretion.

Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1

Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization

Intracellular-Delivery Of A Single-Chain Antibody Against Hepatitis B Core Protein Via Cell-Penetrating Peptide Inhibits Hepatitis B Virus Replication In Vitro

Combinatorial library-based profiling of the antibody response against hepatitis C virus in humans.

Non-neutralizing Epitopes Induce Robust Hepatitis C Virus (Hcv)-Specific Antibody-Dependent CD56+natural Killer Cell Responses in Chronic HCV-infected Patients

Determination of the Human Antibody Response to the Neutralization Epitopes Encompassing Amino Acids 313-327 and 432-443 of Hepatitis C Virus E1e2 Glycoproteins

Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein

Study on the Inhibition of Hepatitis B Virus by Single-chain Fv Fragment

Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.

The characterization and structural basis of a human broadly binding antibody to HBV core protein

A panel of hepatitis C virus glycoproteins for the characterization of antibody responses using antibodies with diverse recognition and neutralization patterns

An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission